Profil Institute Begins Study Participant Screening in Orange County for Diabetes and Obesity Clinical Trials
SAN DIEGO, Oct. 7 /PRNewswire/ -- Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the initiation of patient screening in Orange County for clinical trial eligibility at the company's San Diego clinical facility.
"A growing number of our study participants are from the Orange County and Los Angeles area. We greatly value their participation and wanted to provide a more convenient location for the eligibility screening process," said Dr. Marcus Hompesch, Profil Institute CEO. "Study participants are the cornerstone to discovering new therapies. Without their participation, there would be no advances in clinical treatments."
Profil Institute's screening for eligible study participants in Orange County takes place at Fountain Valley Regional Hospital and Medical Center, in the northwest corner of Orange County.
Profil Institute's facility in San Diego, where the clinical trials are conducted, is a state-of-the-art medical setting, with over 25,000 square feet, 35 patient beds, in-house pharmaceutical services, specialized meal fulfillment and a team of over 100 doctors, nurses, research assistants, technicians and laboratory specialists.
To date, the company has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices.
About Profil™ Institute for Clinical Research, Inc.
Profil Institute is a privately held institute providing high quality early phase clinical research services in diabetes and obesity. Profil Institute uses its expertise to guide the developmental planning, design and actual performance of early phase clinical studies that help in the determination of whether a new compound should be carried forward into the later phases of clinical development. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University.
For more information visit www.profil-research.com.
SOURCE Profil Institute for Clinical Research, Inc.